Clinical trialNCT02513771CompletedPhase 2Interventional

Sitagliptin for Reducing Inflammation and Immune Activation

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment90HIV-1 Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin) reduces inflammation and immune activation markers in HIV-infected men and women when compared to a placebo (inactive medication like a dummy pill). The study evaluated whether taking 100 mg of sitagliptin by mouth daily for 16 weeks is safe and effective for HIV-infected persons on antiretroviral therapy (ART) who do not have diabetes. Sitagliptin is a medication that is used to treat people with diabetes (high blood sugar) but also may reduce inflammation in the body.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Kevin Yarasheski, PhD
Washington University School of Medicine
Study Chair
clinicaltrials.gov ↗
Michael Dube, MD
University of Southern California
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

16 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucla Care Center Crs (601)
Los Angeles, California, United States
University of Southern California (1201)
Los Angeles, California, United States
Harbor-Ucla Med. Ctr. Crs (603)
Torrance, California, United States
Whitman Walker Health Crs (31791)
Washington D.C., District of Columbia, United States
Washington University Crs (2101)
St Louis, Missouri, United States
Columbia Physicians and Surgeons Crs (30329)
New York, New York, United States
Cornell Crs (7804)
New York, New York, United States
University of Rochester Adult Hiv Therapeutic Strategies Network Crs (31787)
Rochester, New York, United States
Unc Aids Crs (3201)
Chapel Hill, North Carolina, United States
Greensboro Crs (3203)
Greensboro, North Carolina, United States
Univ. of Cincinnati Crs (2401)
Cincinnati, Ohio, United States
Case Crs (2501)
Cleveland, Ohio, United States
the Ohio State Univ. Aids Crs (2301)
Columbus, Ohio, United States
Hosp. of the Univ. of Pennsylvania Crs (6201)
Philadelphia, Pennsylvania, United States
Pittsburgh Crs (1001)
Pittsburgh, Pennsylvania, United States
Houston Aids Research Team Crs (31473)
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Placebo for sitagliptinSitagliptin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2015
Primary completion: 13 Dec 2016
Completion: 10 Jan 2017
Last update posted: 18 Jun 2018
Registered enrollment: 90
Registry id: NCT02513771

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.